This is not new, that persons with one kind of cancer are at increased risk to develop a second, different kind of cancer, in their lifetime. It's not exclusive to melanoma.
This JAMA published study looks specifically at patients with metastatic melanoma who received treatment with immune checkpoint inhibitors (ICI): Ipi, nivo, pembro. Below is the link to this study. It's tricky to read, but here is my take away: we must be vigilent in monitoring our primary health in addition to melanoma because there are increased risks for persons with metastatic melanoma:
" The overall risk of developing SPCs in individuals who survived the first
primary melanoma was 65% higher (SIR, 1.65; 95% CI, 1.35-2.00) in the pre-ICIs period and 98%
higher (SIR, 1.98; 95% CI, 1.57-2.45) in the post-ICIs period than the overall cancer incidence rate in
the general population."
jamanetwork.com/journals/ja...
Take care,
missy
